BENGALURU, INDIA | JULY 25, 2026 – In a landmark development for Indian cancer care, Manipal Hospital, Yelahanka, Bengaluru, has become the first healthcare institution in the country to install the Elekta Evo—an advanced, AI-enhanced adaptive CT-Linac platform. This milestone installation enables clinicians to routinely deliver Online Adaptive Radiotherapy (ART), paving the way for highly personalized, precision-led radiation treatments.
The installation builds upon Elekta Evo’s formal Indian debut at AROICON 2025, the nation’s premier radiation oncology conference held in Kolkata.
Addressing India’s Escalating Cancer Burden
Data from the Indian Council of Medical Research (ICMR) highlights a growing national cancer burden, with approximately 1.46 million new cases diagnosed annually. As a significant proportion of these patients present with complex or advanced-stage malignancies requiring radiation, the demand for technologies offering superior accuracy and personalization has never been more critical.
The integration of Elekta Evo fundamentally elevates Manipal Hospital’s radiation oncology capabilities. By embedding adaptive radiotherapy into everyday clinical workflows, the department can dynamically adjust treatment plans to reflect anatomical changes throughout a patient’s care journey. This agility supports informed decision-making without sacrificing operational efficiency or technical precision.
Translating this capability into immediate clinical practice, the oncology team at Manipal Hospital, Yelahanka, has already treated its first patient—an individual with locally advanced rectal cancer—using online adaptive radiotherapy (oART). The patient successfully completed neoadjuvant chemoradiotherapy with minimal radiation-induced side effects, underscoring the platform’s ability to aggressively target tumors while safeguarding surrounding healthy tissue. Clinicians are currently leveraging the system to treat cervical, rectal, and prostate cancers, with patients exhibiting high treatment tolerance and promising early outcomes.
Feras Al Hasan, Head of TIMEA at Elekta, stated The installation of India’s first Elekta Evo at Manipal Hospital marks an important milestone in expanding access to adaptive radiation therapy in the country. Since introducing Evo at AROICON last year, our ambition has been to make this next generation of precision radiation therapy available to clinicians treating increasingly complex cancers. By combining AI-enhanced imaging with online adaptive capabilities on a highly versatile CT-Linac platform, Evo enables clinicians to make more informed treatment decisions throughout a patient’s care journey.”
Dr. Vikram Maiya, Lead Consultant – Radiation Oncology at Manipal Hospital, Yelahanka, added:
“Becoming the first hospital in India to install Elekta Evo reinforces our commitment to bringing the latest advances in cancer care to our patients. The platform enables our radiation oncology teams to adapt treatment to changes in a patient’s anatomy during therapy… Our initial experience across rectal, cervical, and prostate cancer patients has been encouraging, with treatments progressing well and minimal side effects observed so far.”
Cutting-Edge Technology: How Elekta Evo Works
Traditional radiation therapy relies on initial pre-treatment scans, which do not account for daily anatomical shifts, internal organ motion, or tumor shrinkage during a multi-week care regimen. Adaptive Radiotherapy (ART) solves this challenge by re-evaluating and re-planning treatments mid-course.
Elekta Evo delivers this capability through two core technological pillars:
- Iris™ High-Definition AI-Enhanced Imaging: Provides exceptional visualization clarity of both the tumor and adjacent soft tissue structures.
- Elekta ONE® Online Software: Accelerates clinical workflows via AI-assisted automatic contouring, distributed treatment planning, and rapid dose calculation.
Together, these technologies allow oncology teams to perform daily, real-time adjustments with speed and confidence, delivering maximum therapeutic doses to the tumor site while drastically minimizing radiation exposure to healthy tissues.
Disclaimer: Elekta Evo holds Central Drugs Standard Control Organization (CDSCO) registration in India with limited global availability. Elekta ONE® comprises multiple software solutions, some of which may not yet be available in all international markets.
